Fig 1.
Flow chart of the screening and selection of included studies.
Table 1.
Characteristics of studies included in the systematic review.
Fig 2.
Meta-analysis of HbA1C (%) in patients during CIPII treatment compared to that during control treatment (CSII).
Treatment, continuous intraperitoneal insulin infusion (CIPII); Control, continuous subcutaneous insulin infusion (CSII). Studies ordered by effect size (mean difference) and divided into subgroups: HBA1c levels ≤ 53.0 mmol/mol (≤ 7%) and HbA1c levels > 53.0 mmol/mol (> 7%) during control treatment (CSII).
Fig 3.
Funnel plot of HbA1c (%) during CIPII treatment compared to that during control treatment (CSII).
The funnel plot includes diagonal lines representing expected distribution of studies in the absence of heterogeneity (95% of the studies should lie within these diagonal lines). The lines are not strict 95% confidence interval, therefore, referred as ‘pseudo 95% CI’.
Fig 4.
Meta-analysis of fasting blood glucose (mmol/L) in patients during CIPII treatment compared to that during control treatment (CSII).
Treatment, continuous intraperitoneal insulin infusion (CIPII); Control, continuous subcutaneous insulin infusion (CSII). Studies are ordered by effect size (mean difference).
Fig 5.
Meta-analysis of fasting insulin (pmol/L) in patients during CIPII treatment compared to that during control treatment (CSII).
Treatment, continuous intraperitoneal insulin infusion (CIPII); Control, continuous subcutaneous insulin infusion (CSII). Studies ordered by effect size (mean difference).
Fig 6.
Meta-analysis of mean daily insulin (U/24 hours) in patients during CIPII treatment compared to that during control treatment (CSII).
Treatment, continuous intraperitoneal insulin infusion (CIPII); Control, continuous subcutaneous insulin infusion (CSII). Studies ordered by effect size (mean difference).
Fig 7.
Funnel plot of daily insulin dose (U/24 hours) during CIPII treatment compared to that during control treatment (CSII).
The funnel plot includes diagonal lines representing expected distribution of studies in the absence of heterogeneity (95% of the studies should lie within these diagonal lines). The lines are not strict 95% confidence interval, therefore, referred as ‘pseudo 95% CI’.